Under the contract, Trius will receive up to $3m over three years in support of its development efforts.
The current contract aims to create antibiotics that kill bacteria by disrupting cell wall biosynthesis.
Trius chief scientific officer John Finn said the new contract to discover new broad spectrum antibacterial agents that block bacterial cell wall biosynthesis is an exciting complement to their existing programs.